Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

113
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

604
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
604
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

342
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
342
Lipid Absorption01:24

Lipid Absorption

3.7K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
3.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Composite Surrogate Markers of Insulin Resistance: A Real-World Study Using METS-IR and SPISE.

Journal of clinical medicine·2026
Same author

Assessment of attitudes toward weight loss pharmacotherapy among Greek patients living with obesity: a questionnaire-based study.

Hormones (Athens, Greece)·2026
Same author

Risk Factors Associated with Community-Onset Infections Due to Multidrug-Resistant Organisms.

Antibiotics (Basel, Switzerland)·2025
Same author

Stroke in Transcatheter Aortic Valve Implantation (TAVI): A Comprehensive Review.

Journal of clinical medicine·2025
Same author

Cardiovascular disease burden attributable to estimated glomerular filtration rate: Insights from the ATTICA study (2002-2022).

Annals of epidemiology·2025
Same author

Structural radial artery modifications following transradial access: Mechanisms, clinical implications, and preventive strategies.

World journal of cardiology·2025

Related Experiment Video

Updated: Apr 21, 2026

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.3K

Emerging drugs for hyperlipidaemia: an update.

Matilda Florentin1, Michael S Kostapanos, Anastazia Kei

  • 1Medical School, University of Ioannina, Department of Internal Medicine , Ioannina , Greece.

Expert Opinion on Emerging Drugs
|October 31, 2014
PubMed
Summary

Novel lipid-modifying drugs offer potential for managing hypercholesterolaemia and reducing residual cardiovascular disease (CVD) risk beyond statin therapy. Further clinical outcome studies are needed to confirm their role in patient care.

Keywords:
anacetrapibevacetrapibmicrosomal triglyceride transfer protein inhibitorsmipomersenpre-protein convertase subtilisin kexin -9 inhibitors

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K

Related Experiment Videos

Last Updated: Apr 21, 2026

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.3K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipid Metabolism

Background:

  • Hypercholesterolaemia is a major cardiovascular disease (CVD) risk factor.
  • Current statin therapy reduces CVD events but leaves residual risk.
  • Novel lipid-modifying drugs are needed for patients with persistent lipid disorders.

Purpose of the Study:

  • To review lipid-modifying drugs in development since 2010.
  • To discuss their potential clinical applications.
  • To highlight emerging therapeutic targets for lipid management.

Main Methods:

  • Review of lipid-modifying drugs in development.
  • Focus on specific drug classes: CETP inhibitors, MTP inhibitors, antisense oligonucleotides, PCSK9 inhibitors, and HDL mimetics.
  • Analysis of their mechanisms of action and potential clinical roles.

Main Results:

  • Several novel drug classes show promise in modifying lipid profiles.
  • These include cholesterol ester transfer protein (CETP) inhibitors, microsomal triglyceride transfer protein (MTP) inhibitors, PCSK9 inhibitors, and HDL mimetics.
  • Emerging therapies target diverse pathways in lipid metabolism.

Conclusions:

  • Novel lipid-modifying agents may benefit specific patient groups.
  • Further clinical outcome trials are essential to define their definitive role.
  • These drugs represent a potential advancement in managing residual CVD risk.